New data from the UK indicates that the protection obtained with boosted doses against Covid-19 symptoms caused by the micronized variant wanes in about ten weeks.
2022 Survival Guide:Experts draw scenarios for the Corona virus epidemic next year with Micron
There haven’t been enough serious micron cases yet for researchers to calculate the booster’s ability to protect against the most serious spread of disease, but experts believe the extra dose will still be an important ally against hospitalization and death.
The new report from the UK’s Health Safety Agency noted: “It will take a few weeks before the efficacy against acute forms of micron can be estimated.” However, based on experience with previous variants, they are likely to be much larger than the estimates against symptomatic disease.”
Since the discovery of Ômicron, several studies have suggested that the variant is able to avoid antibodies that are produced after vaccination or after infection with the coronavirus.
The new UK report, which included data on people who had received the AstraZeneca, Pfizer or Moderna vaccines, confirmed that immunization – both an initial course of two doses and a booster dose – was less effective and fell faster against Ômicron than against Delta.
Melatonin arrives in Brazil:What is it, what are the benefits of sleep hormone
Among people who received two doses of AstraZeneca, an mRNA-boosted vaccine, made by Pfizer and Moderna, was 60% effective in preventing symptoms two to four weeks after injection. But after ten weeks, Pfizer’s boosted efficacy was only 35%. Moderna’s booster was 45% effective within nine weeks.
For people who received three doses of Pfizer, vaccine efficacy decreased from 70% after one week of booster to 45% after 10 weeks. On the other hand, those immunized with Pfizer and those who received a Moderna booster dose appeared to do better; His vaccine regimen remained 75% effective over nine weeks.
The report, which was based on an analysis of about 148,000 delta cases and 68,000 omicron cases, also included recent data indicating that infections from the new strain are less likely to result in hospitalizations than delta cases. The agency noted that the results should be interpreted with caution, because there were not many cases of microns, and people who contracted the variant may not be representative of the general population.
In a recent interview, Anthony S. Fauci, the US Infectious Diseases Authority, said it was too early to talk about a fourth dose in the country.
Some scholars oppose the fourth application. For them, there is still no evidence that this is necessary and some cells of the immune system may eventually stop responding if too many doses are given.
“Gamers. Unfortunate Twitter teachers. Zombie pioneers. Internet fans. Hardcore thinkers.”